Next Article in Journal
Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
Previous Article in Journal
A Case of Paraphilia with Osteoporosis and Administered with Depot Leuprorelin
Previous Article in Special Issue
Hepatitis B Virus Genotypes in the Kingdom of Bahrain: Prevalence, Gender Distribution and Impact on Hepatic Biomarkers
Open AccessArticle

The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts

1
“Carol Davila” University of Medicine and Pharmacy, 020021 Bucharest, Romania
2
“Cantacuzino” National Medico-Military Institute for Research and Development, 011233 Bucharest, Romania
3
“Victor Babes” Clinical Hospital for Infectious Diseases, 030303 Bucharest, Romania
4
“Prof. N. Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases, 011233 Bucharest, Romania
5
“Carol Davila’ Nephrology Hospital”, 010731 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
Medicina 2019, 55(10), 706; https://doi.org/10.3390/medicina55100706
Received: 28 August 2019 / Revised: 13 October 2019 / Accepted: 16 October 2019 / Published: 20 October 2019
Background and objectives: Warts are the most common lesions caused by human papillomavirus (HPV). Recent research suggests that oxidative stress and inflammation are involved in the pathogenesis of HPV-related lesions. It has been shown that the soluble receptor for advanced glycation end products (sRAGE) may act as a protective factor against the deleterious effects of inflammation and oxidative stress, two interconnected processes. However, in HPV infection, the role of sRAGE, constitutively expressed in the skin, has not been investigated in previous studies. Materials and Methods: In order to analyze the role of sRAGE in warts, we investigated the link between sRAGE and the inflammatory response on one hand, and the relationship between sRAGE and the total oxidant/antioxidant status (TOS/TAS) on the other hand, in both patients with palmoplantar warts (n = 24) and healthy subjects as controls (n = 28). Results: Compared to the control group, our results showed that patients with warts had lower levels of sRAGE (1036.50 ± 207.60 pg/mL vs. 1215.32 ± 266.12 pg/mL, p < 0.05), higher serum levels of TOS (3.17 ± 0.27 vs. 2.93 ± 0.22 µmol H2O2 Eq/L, p < 0.01), lower serum levels of TAS (1.85 ± 0.12 vs. 2.03 ± 0.14 µmol Trolox Eq/L, p < 0.01) and minor variations of the inflammation parameters (high sensitivity-CRP, interleukin-6, fibrinogen, and erythrocyte sedimentation rate). Moreover, in patients with warts, sRAGE positively correlated with TAS (r = 0.43, p < 0.05), negatively correlated with TOS (r = −0.90, p < 0.01), and there was no significant correlation with inflammation parameters. There were no significant differences regarding the studied parameters between groups when we stratified the patients according to the number of the lesions and disease duration. Conclusions: Our results suggest that sRAGE acts as a negative regulator of oxidative stress and could represent a mediator involved in the development of warts. However, we consider that the level of sRAGE cannot be used as a biomarker for the severity of warts. To the best of our knowledge, this is the first study to demonstrate that sRAGE could be involved in HPV pathogenesis and represent a marker of oxidative stress in patients with warts. View Full-Text
Keywords: sRAGE; oxidative stress; inflammation; warts; HPV sRAGE; oxidative stress; inflammation; warts; HPV
Show Figures

Figure 1

MDPI and ACS Style

Mitran, C.I.; Nicolae, I.; Tampa, M.; Mitran, M.I.; Caruntu, C.; Sarbu, M.I.; Ene, C.D.; Matei, C.; Ionescu, A.C.; Georgescu, S.R.; Popa, M.I. The Relationship between the Soluble Receptor for Advanced Glycation End Products and Oxidative Stress in Patients with Palmoplantar Warts. Medicina 2019, 55, 706.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop